Sunshine Biopharma (NASDAQ:SBFM) Trading Down 1.1% – Should You Sell?

Shares of Sunshine Biopharma, Inc. (NASDAQ:SBFMGet Free Report) dropped 1.1% during trading on Wednesday . The company traded as low as $2.61 and last traded at $2.67. Approximately 66,194 shares traded hands during mid-day trading, a decline of 37% from the average daily volume of 105,548 shares. The stock had previously closed at $2.70.

Analyst Ratings Changes

Separately, Aegis reissued a “buy” rating and issued a $15.00 target price on shares of Sunshine Biopharma in a research note on Thursday, December 5th.

Check Out Our Latest Report on Sunshine Biopharma

Sunshine Biopharma Price Performance

The stock has a 50 day simple moving average of $2.91 and a two-hundred day simple moving average of $2.67. The company has a market cap of $3.05 million, a price-to-earnings ratio of -0.02 and a beta of 1.33.

Sunshine Biopharma (NASDAQ:SBFMGet Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $9.00 by ($9.94). Sunshine Biopharma had a negative net margin of 12.82% and a negative return on equity of 17.89%. The firm had revenue of $8.44 million during the quarter.

Sunshine Biopharma Company Profile

(Get Free Report)

Sunshine Biopharma, Inc, a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products.

Featured Articles

Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.